Clinical Pharmacology & Therapeutics - Abstract of article: A Horizon-Prioritizing Method Can Identify Gaps Among Genomic Application Guidelines

Clinical Pharmacology & Therapeutics - Abstract of article: A Horizon-Prioritizing Method Can Identify Gaps Among Genomic Application Guidelines

Evidence Matters in Genomic Medicine: Pharmacogenomics

New CDC blog post: Evidence matters in genomic medicine- round 4: Where are we with   pharmacogenomic tests?

CDC Horizon-prioritizing method can identify gaps in genomic application guidelines. 
L Li Clinical Pharmacology and Therapeutics, April 2014

Prioritizing genomic applications for action by level of evidence: A horizon-scanning method. 
W D Dotson et al. Clinical Pharmacology and Therapeutics, April 2014

CDC table of genomic applications and tests by level of evidence

Clinical Pharmacology & Therapeutics (2014); 95 4, 368–369. doi:10.1038/clpt.2014.16

A Horizon-Prioritizing Method Can Identify Gaps Among Genomic Application Guidelines

L Li¹

¹Department of Medical and Molecular Genetics, School of Medicine, Indiana University, Indianapolis, Indiana, USA

Correspondence: L Li, (lali@iupui.edu)

Topof page

Abstract

In light of the increasing need by decision makers for a method of evaluating genomic applications based on the weight of evidence for their efficacy, several agencies have developed systems of classification. Here I review the horizon-scanning method for prioritizing genomics applications as described by Dotson et al. in this issue of CPT. Using the examples of the authors’ Tier 1/Green classification for KRAS and Tier 2/Yellow for TPMT, I discuss differences between the guidelines issued by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and those by the National Comprehensive Cancer Network (NCCN). Additionally, I offer suggestions regarding classification of the Tier 3/Red genomics applications and the reproducibility of the data-curating algorithm of the horizon-scanning method.